Percutaneous liver biopsy is a proven way to rate the fibrosis stage both in hepatitis in chronic hepatitis C patients and hepatitis B patients. But it is uncomfortable for patients, risks complications and is prone to assembling errors.
Reporting at ID Week 2015 in San Diego, CA, Tuma Demirdal, DR, and colleagues at the Katip Celebi University in Izmir, Turkey compared these invasive tests with non-invasive methods.
They looked at 236 patients with chronic hepatitits C and hepatitis B who had ultrasound guided liver biopsy over a seven year period Histological grading of necroinflammation and fibrosis ere performed according to Knodell an ISAK scoring systems. APRI, n-APRI, FIB-4, FI scores were calculated.
Labels: Fibrosis, hepatitis B, hepatitis C, liver biopsy, non-invasive methods